Navigation Links
Vion Updates Conference Call Information
Date:11/4/2008

NEW HAVEN, Conn., Nov. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced updated call information for its conference call on Thursday, November 6, 2008 to discuss its 2008 third quarter financial results.

The call will begin at 8:30 a.m. Eastern Time.

To participate in the conference call, please dial (866) 831-6270 in the U.S., ((617) 213-8858 for international callers), at least 15 minutes before the start of the call. When prompted for a pass code, please enter 85439318.

An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 37383579. The replay will be available through Thursday, November 20, 2008.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R), VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of laromustine (Cloretazine(R), VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to file a New Drug Application or obtain regulatory approval for its products, particularly laromustine (Cloretazine,VNP40101M), delays in the regulatory approval process or delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ended June 30, 2008. In particular, there can be no assurance as to the results of any of the Vion's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT:

Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance
2. Gonzaga Online Updates Communications Masters Program To Meet the Needs of Today's Professionals
3. SpectraScience Announces Updates
4. Vista Partners Updates Coverage on MediciNova Inc. (NASDAQ: MNOV); Maintains $8.50 Price Target
5. US Preventive Services Task Force updates prostate cancer screening recommendations
6. Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data
7. Jazz Pharmaceuticals Announces Development Timeline Updates
8. Carriage Services Updates Company & Investment Profile
9. KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings
10. Novadaq Updates on OPTTX Data Reported at Euroretina
11. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... ... The Touchpoint Solution’s new neuroscience wearable, Buzzies, generated over $100K in sales online ... $25,000 on Kickstarter to bring to the market what people are calling ... inventor, says she feels like she stumbled upon a miracle that she wants other ...
(Date:12/6/2016)... ... ... Of the variety of ingredients in the food supply, few spark more ... beliefs that hot dogs include “everything but the oink,” today’s wieners are made from ... meat and poultry in a hot dog recipe can add flavor, keep hot dogs ...
(Date:12/6/2016)... ... December 06, 2016 , ... Public middle and high schools ... apply for a 2016/2017 California Casualty Thomas R. Brown Athletics Grant. The application ... receive up to $3,000. , The grant is named after California Casualty ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... charity, is thrilled to formally announce its Not a Moment to Lose fundraising ... Lose will rally supporters dedicated to declaring victory over cancer. The campaign aims ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016  Nearly 30 million people in ... the epidemic of diabetes. 1 However, nearly 40% ... glucose levels (hyperglycemia) and significant glucose variability. 2 These ... including cardiovascular events. If left untreated, hyperglycemia can lead ... disease or blindness. 3 As part ...
(Date:12/6/2016)... 6, 2016   Sienna Biopharmaceuticals, Inc. ... and aesthetics company, today announced it has ... pharmaceutical company focused on developing first-in-class topical ... psoriasis, atopic dermatitis and pruritus (itch). Under ... make an undisclosed upfront payment in cash ...
(Date:12/6/2016)... 6, 2016  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... focused on the development of novel therapies for ... U.S. Food and Drug Administration (FDA) has granted ... of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a novel, ... selectively regulates the expression of genes believed to ...
Breaking Medicine Technology: